Zantac exec testifies on claims that heat degraded heartburn drug into cancer-causing substance The plaintiff’s lawyers argue the drug degraded into NDMA when exposed to hot, humid conditions.

Zantac, once one of the world's best-selling drugs, is now at the center of a massive legal battle. For decades, its manufacturer, Glaxo (now GlaxoSmithKline or GSK), allegedly concealed the ...

Zantac is a drug that companies have pulled from the market due to concerns about its cancer risk. ... NDMA levels increase when the drug is in storage at higher-than-normal room temperatures.

To produce a three million nanogram potential dose, Valisure manipulated the evidence - heating the ranitidine to 266 degrees Fahrenheit rather than normal storage levels or a human body temperature ...

The suit alleges ranitidine transforms over time into NDMA both within the human body and during transportation and storage of the drug. ... Zantac, first approved in 1983, ...

Lawyers make closing pitches in first jury trial over Zantac cancer claims The jury of nine women and three men will now deliberate over whether the heartburn drug caused an 89-year-old Brookfield ...

Illinois resident Angela Valadez had alleged that her cancer was a result of taking over-the-counter Zantac and generic versions of it from 1995 to 2014.

A jury in Chicago on Thursday rejected an Illinois woman’s claim that the now discontinued heartburn drug Zantac caused her colon cancer, in the first trial out of thousands of lawsuits making ...

The science that led to Zantac’s withdrawal is very different from the basis of the recently dismissed Zantac litigation (“The Zantac Scare and Junk Science,” Review & Outlook, Dec. 9). The ...